Used in pharmaceutical research as a potent and selective inhibitor of Janus kinase 1 (JAK1), this compound shows promise in the treatment of autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Its spirocyclic structure enhances selectivity and metabolic stability, making it a valuable scaffold in the development of oral JAK inhibitors. It has also been investigated for potential use in oncology due to the role of JAK-STAT signaling in certain cancers. Preclinical studies highlight its favorable pharmacokinetic profile and reduced off-target effects compared to earlier kinase inhibitors.